Advertisement

Document › Details
Genomica SAU. (1/18/18). "Press Release: Genomica Opens Its First Subsidiary in China". Madrid.
![]() |
Organisation | Genomica S.A.U. |
Group | PharmaMar (Group) | |
Organisation 2 | Genomica (Wuhan, China) | |
Group | PharmaMar (Group) | |
![]() |
Product | in vitro diagnostics (IVD) |
Product 2 | venture capital | |
![]() |
Person | Cospedal, Rosario (Zeltia 201211 CEO of Genomica S.A.U.) |
• The opening of the legal entity in the country represents an unprecedented milestone as it is the first Spanish In Vitro diagnostic company with headquarters in China.
• China is experiencing a period of economic prosperity thanks to the opening of investment of international companies in the country.
GENOMICA opens its first subsidiary in Wuhan, China. The office, established in the East Lake High Tech Zone, will serve as an operations center to increase the presence of the company (PharmaMar Group) not only in China, but also in other Asian-Pacific countries. Its products are currently distributed in several territories of this region.
GENOMICA, which already markets its products to distributors in this region, will benefit from its new position and will be able to maintain a direct commercial relationship with its customers.
The company has formed a new organizational structure in which it has incorporated new professionals within China to effectively face the next challenges at the forefront of the newly opened subsidiary.
As Rosario Cospedal, Managing Director of GENOMICA, said, "the opening of the new subsidiary in China represents a key advance in the company's strategic plan. This is crucial for GENOMICA, not only because the Company is now present in one of the most powerful markets in the world, it also give us the opportunity to continue with the company’s expansion through Asia Pacific.”
China, currently with its rising economic growth, presents one of the largest markets for medical equipment in the world. In the last year, the demand for medical devices has been greater than the supply, mainly due to the increase in the average age of the Chinese population.
GENOMICA appears at a very propitious time to introduce its diagnostic solutions and consolidate its global expansion plan.
With the opening of this filial, GENOMICA is now physically present in Scandinavia, Brazil and China from where it operates in the world´s main markets.
Record changed: 2023-06-05 |
Advertisement

More documents for PharmaMar (Group)
- [1] PharmaMar S.A.. (2/17/20). "Press Release: PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer". Madrid & Dublin....
- [2] PharmaMar S.A.. (3/25/19). "Press Release: PharmaMar Announces Positive Results in Its Lurbinectedin Monotherapy Trial for Small Cell Lung Cancer". Madrid....
- [3] PharmaMar S.A.. (2/14/18). "Press Release: PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates". Madrid....
- [4] PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid)....
- [5] PharmaMar S.A.. (5/18/17). "Press Release: PharmaMar Announces New Data with Its Compounds Yondelis and Lurbinectedin during ASCO 2017". Madrid....
- [6] PharmaMar S.A.. (5/17/17). "Press Release: PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries". Madrid....
- [7] PharmaMar S.A.. (5/4/17). "Press Release: Aplidin Receives Orphan Drug Status for the Treatment of Multiple Myeloma in Switzerland". Madrid....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top